# Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

> **NCT02828878** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cellect Biotechnology** · enrollment: 12 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **BIOLOGICAL:** Allogeneic MPBC transplantation from matched related donor

## Key facts

- **NCT ID:** NCT02828878
- **Lead sponsor:** Cellect Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828878, "Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02828878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*